Empirical MRSA Coverage for Nonpurulent Cellulitis: Swinging the Pendulum Away From Routine Use
Cellulitis is an infection of the deep dermis and subcutaneous tissue, manifesting as expanding erythema, edema, and warmth of the skin. In most instances of cellulitis, the causative microorganism cannot be definitively determined. However, based on studies using blood cultures, other laboratory markers, and clinical response to β-lactam antimicrobials, the vast majority of cellulitis is thought to be caused by β-hemolytic streptococci. Staphylococci, including methicillin-resistant Staphylococcus aureus, are a less common cause of cellulitis and are more likely to be encountered in cases of purulent cellulitis or abscess formation. Here, Shuman et al examine whether combination antimicrobial therapy with trimethoprim-sulfamethoxazole and a β-lactam is superior to treatment with cephalexin alone for nonpurulent cellulitis without abscess..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:317 |
|---|---|
| Enthalten in: |
The journal of the American Medical Association / Englische Ausgabe - 317(2017), 20, Seite 2070-2071 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shuman, Emily K [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1001/jama.2017.5654 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1994213493 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1994213493 | ||
| 003 | DE-627 | ||
| 005 | 20230715052714.0 | ||
| 007 | tu | ||
| 008 | 170721s2017 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1001/jama.2017.5654 |2 doi | |
| 028 | 5 | 2 | |a PQ20170721 |
| 035 | |a (DE-627)OLC1994213493 | ||
| 035 | |a (DE-599)GBVOLC1994213493 | ||
| 035 | |a (PRQ)a1127-1859c5b0132ba6bca0c3dc695e95371355eb68e347a7a2c06f5b7032488656ce0 | ||
| 035 | |a (KEY)0027940420170000317002002070empiricalmrsacoveragefornonpurulentcellulitisswing | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 100 | 1 | |a Shuman, Emily K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Empirical MRSA Coverage for Nonpurulent Cellulitis: Swinging the Pendulum Away From Routine Use |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Cellulitis is an infection of the deep dermis and subcutaneous tissue, manifesting as expanding erythema, edema, and warmth of the skin. In most instances of cellulitis, the causative microorganism cannot be definitively determined. However, based on studies using blood cultures, other laboratory markers, and clinical response to β-lactam antimicrobials, the vast majority of cellulitis is thought to be caused by β-hemolytic streptococci. Staphylococci, including methicillin-resistant Staphylococcus aureus, are a less common cause of cellulitis and are more likely to be encountered in cases of purulent cellulitis or abscess formation. Here, Shuman et al examine whether combination antimicrobial therapy with trimethoprim-sulfamethoxazole and a β-lactam is superior to treatment with cephalexin alone for nonpurulent cellulitis without abscess. | ||
| 650 | 4 | |a Trimethoprim | |
| 650 | 4 | |a Erythema | |
| 650 | 4 | |a MRSA | |
| 650 | 4 | |a Drug resistance | |
| 650 | 4 | |a Cephalexin | |
| 650 | 4 | |a Edema | |
| 650 | 4 | |a Cellulitis | |
| 650 | 4 | |a Amides | |
| 650 | 4 | |a Methicillin | |
| 650 | 4 | |a Staphylococcus aureus | |
| 650 | 4 | |a Markers | |
| 650 | 4 | |a Infections | |
| 650 | 4 | |a Dermis | |
| 650 | 4 | |a Skin | |
| 650 | 4 | |a Sulfamethoxazole | |
| 650 | 4 | |a Staphylococcus infections | |
| 650 | 4 | |a Drug therapy | |
| 650 | 4 | |a Staphylococcus | |
| 650 | 4 | |a Therapy | |
| 650 | 4 | |a Antimicrobial agents | |
| 650 | 4 | |a Blood | |
| 650 | 4 | |a Bacterial infections | |
| 650 | 4 | |a Cultures | |
| 650 | 4 | |a Skin (anatomy) | |
| 650 | 4 | |a Trimethoprim-sulfamethoxazole | |
| 650 | 4 | |a Antiinfectives and antibacterials | |
| 700 | 1 | |a Malani, Preeti N |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The journal of the American Medical Association / Englische Ausgabe |d Chicago, Ill. : American Medical Association, 1883 |g 317(2017), 20, Seite 2070-2071 |w (DE-627)129077798 |w (DE-600)2958-0 |w (DE-576)014410338 |x 0254-9077 |7 nnns |
| 773 | 1 | 8 | |g volume:317 |g year:2017 |g number:20 |g pages:2070-2071 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1001/jama.2017.5654 |3 Volltext |
| 856 | 4 | 2 | |u http://dx.doi.org/10.1001/jama.2017.5654 |
| 856 | 4 | 2 | |u https://search.proquest.com/docview/1907809174 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_252 | ||
| 912 | |a GBV_ILN_2008 | ||
| 912 | |a GBV_ILN_2414 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4082 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4219 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4309 | ||
| 951 | |a AR | ||
| 952 | |d 317 |j 2017 |e 20 |h 2070-2071 | ||